Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials

NCT03207256 ↗

Phase 2 Terminated 51 enrolled TG Therapeutics, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an open label compassionate use trial of Ublituximab and TGR-1202 in combination or as single agents in patients currently receiving treatment on Ublituximab and/or TGR-1202 trials with B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia.

Timeline

Start: 2017-08-09
Primary completion: 2022-05-25
Completion: 2022-06-24

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ublituximab	Monoclonal antibody	—	Intravenous
Subject	Umbralisib	Small molecule	—	Oral

Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials

Summary

Timeline

Drugs

Indications